<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05612789</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 07422</org_study_id>
    <secondary_id>Penn IRB# 851615</secondary_id>
    <nct_id>NCT05612789</nct_id>
  </id_info>
  <brief_title>Improve Outcomes for Older Allogeneic Transplant Recipients</brief_title>
  <official_title>Intervening on Frailty to Improve Outcomes for Older Allogeneic Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center at Penn Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center at Penn Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional pilot study to determine whether implementation of a supervised&#xD;
      exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary&#xD;
      objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled.&#xD;
      Evaluable subjects are defined as those participating in the exercise intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2023</start_date>
  <completion_date type="Anticipated">November 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of enrolled subjects who participate in the supervised exercise program</measure>
    <time_frame>From 3 months prior to HCT to 100 days after HCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median number of exercise sessions delivered pre-HCT and post-HCT.</measure>
    <time_frame>From 3 months prior to HCT to 100 days after HCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital LOS for HCT</measure>
    <time_frame>From date of randomization until the date of first documented discharge from the hospital, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of readmission</measure>
    <time_frame>From time of discharge from initial hospital stay up through 1-2 years after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month and 1-year overall mortality</measure>
    <time_frame>From day 0 of HCT to 6 months and 1-year] 6. 1-year and 2-year OS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year and 2-year OS</measure>
    <time_frame>From day 0 of HCT to 1-year and 2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year and 2-year PFS</measure>
    <time_frame>From day 0 of HCT to 1-year and 2-years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Allogeneic Transplantation</condition>
  <arm_group>
    <arm_group_label>Cohort A (Prehab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-frail and frail subjects will attend at least twice weekly exercise sessions with a physical therapist and be given an exercise program to complete at home prior to admission for HCT. Patients enrolled in this cohort can continue on to Cohort B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (Rehab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients 60 years and older upon discharge from their initial hospital stay for HCT will attend at least weekly exercise sessions with a physical therapist and be given an exercise program to complete at home with sessions continued through Day +100 after HCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Program (Cohort A Prehab)</intervention_name>
    <description>Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.</description>
    <arm_group_label>Cohort A (Prehab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Program (Cohort B Rehab)</intervention_name>
    <description>All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.</description>
    <arm_group_label>Cohort B (Rehab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort A (Prehab)&#xD;
&#xD;
          1. Age 60 years or older.&#xD;
&#xD;
          2. Planned allogeneic HCT in the next 1-6 months.&#xD;
&#xD;
          3. Hematological malignancy as the indication for HCT.&#xD;
&#xD;
          4. Pre-frail or frail by Fried frailty phenotype.&#xD;
&#xD;
        Cohort B (Rehab)&#xD;
&#xD;
          1. Age 60 years or older.&#xD;
&#xD;
          2. Planned allogeneic HCT or HCT within the last 30 days.&#xD;
&#xD;
          3. Hematological malignancy as the indication for HCT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohorts A and B&#xD;
&#xD;
        1. Comorbid disability or illness that prevents safe exercise.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon McCurdy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqui Rick</last_name>
    <phone>2152209675</phone>
    <email>Jacqui.Rick@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Penn Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqui Rick</last_name>
      <phone>215-220-9675</phone>
      <email>Jacqui.Rick@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>October 21, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>February 21, 2023</last_update_submitted>
  <last_update_submitted_qc>February 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

